Alessandro Casini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1394454/publications.pdf

Version: 2024-02-01

72	2,099	279798 23	243625 44
papers	citations	h-index	g-index

75	75	75	2062
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Congenital Fibrinogen Disorders: An Update. Seminars in Thrombosis and Hemostasis, 2013, 39, 585-595.	2.7	218
2	Natural history of patients with congenital dysfibrinogenemia. Blood, 2015, 125, 553-561.	1.4	138
3	Risks of Venous Thromboembolism After Cesarean Sections: A Meta-Analysis. Chest, 2016, 150, 572-596.	0.8	122
4	Fibrin(ogen) in human disease: both friend and foe. Haematologica, 2020, 105, 284-296.	3.5	121
5	Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. Journal of Thrombosis and Haemostasis, 2015, 13, 909-919.	3.8	116
6	Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1887-1890.	3.8	98
7	Clinical Features and Management of Congenital Fibrinogen Deficiencies. Seminars in Thrombosis and Hemostasis, 2016, 42, 366-374.	2.7	89
8	A fibrin biofilm covers blood clots and protects from microbial invasion. Journal of Clinical Investigation, 2018, 128, 3356-3368.	8.2	88
9	Laboratory and Genetic Investigation of Mutations Accounting for Congenital Fibrinogen Disorders. Seminars in Thrombosis and Hemostasis, 2016, 42, 356-365.	2.7	80
10	Thromboprophylaxis and laboratory monitoring for in-hospital patients with Covid-19 - a Swiss consensus statement by the Working Party Hemostasis. Swiss Medical Weekly, 2020, 150, w20247.	1.6	77
11	Thrombotic complications of myeloproliferative neoplasms: risk assessment and riskâ€guided management. Journal of Thrombosis and Haemostasis, 2013, 11, 1215-1227.	3.8	67
12	Genetics, diagnosis and clinical features of congenital hypodysfibrinogenemia: a systematic literature review and report of a novel mutation. Journal of Thrombosis and Haemostasis, 2017, 15, 876-888.	3.8	57
13	Acquired factor XIII deficiency: a therapeutic challenge. Thrombosis and Haemostasis, 2013, 109, 479-487.	3.4	53
14	Clinical Consequences and Molecular Bases of Low Fibrinogen Levels. International Journal of Molecular Sciences, 2018, 19, 192.	4.1	43
15	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. HemaSphere, 2019, 3, e286.	2.7	43
16	Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines. Swiss Medical Weekly, 2020, 150, w20301.	1.6	39
17	Management of congenital quantitative fibrinogen disorders: a Delphi consensus. Haemophilia, 2016, 22, 898-905.	2.1	38
18	Minimal factor XIII activity level to prevent major spontaneous bleeds. Journal of Thrombosis and Haemostasis, 2017, 15, 1728-1736.	3.8	34

#	Article	IF	Citations
19	Mutational Epidemiology of Congenital Fibrinogen Disorders. Thrombosis and Haemostasis, 2018, 118, 1867-1874.	3.4	32
20	The (Patho)physiology of Fibrinogen Î³â€². Seminars in Thrombosis and Hemostasis, 2016, 42, 344-355.	2.7	28
21	A Novel Nonsense Mutation in FGB (c.1421G>A; p.Trp474Ter) in the Beta Chain of Fibrinogen Causing Hypofibrinogenemia with Bleeding Phenotype. Biomedicines, 2020, 8, 605.	3.2	26
22	Can the phenotype of inherited fibrinogen disorders be predicted?. Haemophilia, 2016, 22, 667-675.	2.1	25
23	Perioperative management of a severe congenital hypofibrinogenemia with thrombotic phenotype. Thrombosis Research, 2020, 188, 1-4.	1.7	25
24	Fibrinogen concentrates in hereditary fibrinogen disorders: Past, present and future. Haemophilia, 2020, 26, 25-32.	2.1	24
25	Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management. Blood Reviews, 2021, 48, 100793.	5.7	24
26	FGB mutations leading to congenital quantitative fibrinogen deficiencies: An update and report of four novel mutations. Thrombosis Research, 2014, 133, 868-874.	1.7	23
27	Fibrin clot structure in patients with congenital dysfibrinogenaemia. Thrombosis Research, 2016, 137, 189-195.	1.7	22
28	Successful pregnancy under fibrinogen substitution in a woman with congenital afibrinogenaemia complicated by a postpartum venous thrombosis. Haemophilia, 2015, 21, e108-10.	2.1	19
29	Thrombin generation and fibrin clot structure after vitamin D supplementation. Endocrine Connections, 2019, 8, 1447-1454.	1.9	19
30	Hypofibrinogenemia and liver disease: a new case of Aguadilla fibrinogen and review of the literature. Haemophilia, 2015, 21, 820-827.	2.1	18
31	How I treat dysfibrinogenemia. Blood, 2021, 138, 2021-2030.	1.4	18
32	Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia. Blood, 2021, 137, 3127-3136.	1.4	18
33	Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVIDâ€19: The Swiss COVIDâ€HEP randomized clinical trial. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	18
34	Diagnosis of congenital fibrinogen disorders. Annales De Biologie Clinique, 2016, 74, 405-412.	0.1	15
35	Obstetrical and postpartum complications in women with hereditary fibrinogen disorders: A systematic literature review. Haemophilia, 2019, 25, 747-754.	2.1	15
36	Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. Swiss Medical Weekly, 2020, 150, w20422.	1.6	15

#	Article	IF	Citations
37	Protein modelling to understand FGB mutations leading to congenital hypofibrinogenaemia. Haemophilia, 2017, 23, 583-589.	2.1	14
38	Validation of the Disease Risk Index for Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after T Cell Depletion. Biology of Blood and Marrow Transplantation, 2014, 20, 1322-1328.	2.0	13
39	A Unique Factor XIII Mutation in Southeastern Iran with an Unexpectedly High Prevalence: Khash Factor XIII. Seminars in Thrombosis and Hemostasis, 2019, 45, 043-049.	2.7	10
40	Safety of variceal band ligation in patients with cirrhosis and portal vein thrombosis treated with anticoagulant therapy: A retrospective study. European Journal of Gastroenterology and Hepatology, 2020, 32, 395-400.	1.6	10
41	Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis. Journal of Hepatology, 2020, 73, 967-970.	3.7	10
42	Congenital structural and functional fibrinogen disorders: a primer for internists. Polish Archives of Internal Medicine, 2019, 129, 913-920.	0.4	10
43	Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort. Blood Advances, 2022, 6, 2884-2892.	5.2	10
44	Fibrinogen Mahdia: A congenitally abnormal fibrinogen characterized by defective fibrin polymerization. Haemophilia, 2017, 23, e340-e347.	2.1	9
45	From Routine to Research Laboratory: Strategies for the Diagnosis of Congenital Fibrinogen Disorders. Hamostaseologie, 2020, 40, 460-466.	1.9	9
46	Whole Blood Thromboelastometry by ROTEM and Thrombin Generation by Genesia According to the Genotype and Clinical Phenotype in Congenital Fibrinogen Disorders. International Journal of Molecular Sciences, 2021, 22, 2286.	4.1	9
47	Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland. Swiss Medical Weekly, 2020, 150, w20210.	1.6	9
48	Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies. Bone Marrow Research, 2015, 2015, 1-7.	1.7	8
49	Impaired factor XIII activation in patients with congenital afibrinogenemia. Haematologica, 2019, 104, e111-e113.	3.5	8
50	Pulmonary embolism and fatal stroke in a patient with severe factor XI deficiency after bariatric surgery. Blood Coagulation and Fibrinolysis, 2013, 24, 347-350.	1.0	7
51	Comparison of different activators of coagulation by turbidity analysis of hereditary dysfibrinogenemia and controls. Blood Coagulation and Fibrinolysis, 2021, 32, 108-114.	1.0	7
52	Recurrent Syncope due to Esophageal Squamous Cell Carcinoma. Case Reports in Oncology, 2011, 4, 433-438.	0.7	6
53	Fibrin clot properties to assess the bleeding phenotype in unrelated patients with hypodysfibrinogenemia due to novel fibrinogen mutations. Thrombosis Research, 2021, 197, 56-64.	1.7	6
54	Fibrinogen geneva II. Blood Coagulation and Fibrinolysis, 2014, 25, 280-282.	1.0	5

#	Article	IF	Citations
55	Heterozygous FGA p.Asp473Ter (fibrinogen Nieuwegein) presenting as antepartum cerebral thrombosis. Thrombosis Research, 2018, 163, 185-189.	1.7	4
56	Congenital Fibrinogen Disorders. , 2018, , 163-181.		4
57	The impact of haemophilia on the social status and the healthâ€related quality of life in adult Lebanese persons with haemophilia. Haemophilia, 2019, 25, 264-269.	2.1	4
58	A homozygous duplication of the <I>FGG</i> exon 8-intron 8 junction causes congenital afibrinogenemia. Lessons learned from the study of a large consanguineous Turkish family. Haematologica, 2022, 107, 1064-1071.	3.5	3
59	Prospective Data Collection on Patients with Fibrinogen and Factor XIII Deficiencies: Prelimary Results of the PRO-RBDD Project. Blood, 2014, 124, 2838-2838.	1.4	3
60	Impact of Fibrinogen Infusion on Thrombin Generation and Fibrin Clot Structure in Patients with Inherited Afibrinogenemia. Thrombosis and Haemostasis, 2022, 122, 1461-1468.	3.4	3
61	Factor concentrates for rare congenital coagulation disorders: where are we now?. Expert Opinion on Orphan Drugs, 2016, 4, 49-62.	0.8	2
62	Impact of pneumatic tube system transport for the monitoring of heparin therapy. Thrombosis Research, 2017, 158, 35-37.	1.7	1
63	A novel fibrinogen mutation: FGA g. 3057 CÂ›ÂT (p. Arg104Â›ÂCys) impairs fibrinogen secretion. BMC Hematology, 2017, 17, 22.	2.6	1
64	Identification and expression of a novel heterozygous frameshift mutation in FGA accounting for congenital hypofibrinogenemia in carriers of severe hemophilia A. Thrombosis Research, 2020, 193, 5-8.	1.7	1
65	Molecular characterization of two hypofibrinogenemic patients associated with a novel FGG IVS6+23T>A substitution and a previously reported FGB IVS6â€10_16delTTTG deletion. Haemophilia, 2020, 26, e194-e197.	2.1	1
66	A Unique Case of Acquired Hemophilia A Presenting with Transient Ischemic Attack. Acta Haematologica, 2021, 144, 88-90.	1.4	1
67	Afibrinogenemia with two compound heterozygous mutations in FGA gene. Haemophilia, 2021, 27, e641-e644.	2.1	1
68	Novel missense mutations affecting the structure of the conserved fibrinogen BÎ² C-terminal domain cause congenital hypofibrinogenemia. Thrombosis Research, 2021, 206, 5-8.	1.7	1
69	Hemizygous FGG p.Ala108Gly in a hypofibrinogenemic patient with a heterozygous 14.8 Mb deletion encompassing the entire fibrinogen gene cluster. Haemophilia, 2022, 28, .	2.1	1
70	Global fibrinolytic profile in patients with chronic thromboembolic pulmonary hypertension. , 2015, , .		0
71	Congenital Disorders of Fibrinogen: Clinical Presentations, Diagnosis and Management. , 2016, , 243-254.		0
72	Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study). Blood, 2016, 128, 207-207.	1.4	0